Background: Medial artery calcification develops in diabetes, chronic kidney disease, and as part of the aging process. It is associated with increased morbidity and mortality in vascular patients. Bone morphogenetic proteins (BMPs) have previously been implicated in the initiation and progression of vascular calcification. We thus evaluated whether dorsomorphin homologue 1 (DMH1), a highly selective BMP inhibitor, could attenuate vascular calcification in vitro and in an organ culture model of medial calcification. Methods: Confluent human aortic smooth muscle cells (SMCs) were cultured in calcification medium containing 3.0 mM inorganic phosphate (Pi) for 7 days with or without DMH1. Medial calcification was assessed using an aortic organ culture model. Calcification was visualized by alizarin red S staining, and calcium concentration was assessed by an o-cresolphthalein complexone calcium assay. Osteogenic cell and vascular SMC markers were determined by Western blot, quantitative reverse transcription polymerase chain reaction, and immunohistochemical staining. Results: DMH1 reduced Pi-induced calcium deposition in human SMCs. It also antagonized human recombinant BMP2-induced calcium accumulation. Western blot further revealed that DMH1 was able to block Pi-mediated upregulation of the osteoblast markers osterix and alkaline phosphatase and downregulation of the SMC markers smooth muscle myosin heavy chain and SM22a as well as p-Smad1/5/8, suggesting that DMH1 may regulate SMC osteogenic differentiation through the BMP/Smad1/5/8 signaling pathway. Finally, using an ex vivo aortic ring organ culture model, we observed that DMH1 reduces Pi-induced aortic medial calcification. Conclusions: The selective BMP inhibitor DMH1 can inhibit calcium accumulation in vascular SMCs and arterial segments exposed to elevated phosphate levels. Such small molecules may have clinical utility in reducing medial artery calcification in our population of vascular patients. (J Vasc Surg 2017;66:586-93.) 
Arterial calcification is associated with increased morbidity and mortality in patients with cardiovascular disease. 1, 2 It predicts amputation in a manner that is independent of the ankle-brachial index and atherosclerosis risk factors. 3 Higher scores are seen in patients with foot ulcers even after adjusting for the amount of occlusive disease. 4 Lesion calcification is associated with higher restenosis rates and decreased patency after endovascular superficial femoral artery intervention in patients with diabetes. 5 Arterial calcification occurs in two basic forms that correlate with its location within the arterial wall. It is seen in the intima in association with atherosclerotic plaques and in the media, where it involves elastin and develops through mechanisms associated with the metabolic disturbances. [6] [7] [8] Calcification of arteries was previously thought to be a passive process that involved precipitation of calcium phosphate crystals onto plaque. It is now known, however, to be a tightly regulated process controlled by an array of stimulators and inhibitors. 9, 10 Recent experimental findings suggest that a variety of cellular mechanisms involving microRNAs, 11 endoplasmic reticulum stress, 12 the inflammasome, 13 and autophagy 14 are also involved in its regulation. For these reasons, it is now considered to be an independent biologic process that contributes to poor outcomes in patients with cardiovascular diseases.
Bone morphogenetic proteins (BMPs) provide critical signals for determining cell fate and function, and they are implicated in the development of vascular calcification. 15, 16 BMP2 is enriched in calcified arteries, and elevation of smooth muscle cell (SMC)-specific BMP2 accelerates vascular calcification in hyperlipidemic mice, suggesting that BMP2 plays a crucial role. 17, 18 These studies suggest that the BMP signaling pathway is a promising target for interrupting pathologic arterial calcification.
A highly selective second generation of BMP inhibitor has recently been developed that specifically targets BMP signaling but not vascular endothelial growth factor (VEGF) and angiogenesis. 19 Dorsomorphin homologue 1 (DMH1) is one such highly selective molecule that has been shown to reduce BMP signaling in cell culture and in vitro models. 19 The effect of DMH1 on SMCs grown under calcifying conditions and on whole arterial segments, however, has not been studied. In this study, we investigated the effect of DMH1, a highly selective smallmolecule inhibitor of the BMP type 1 receptor, on vascular SMCs in vitro and medial artery calcification in an organ culture model system.
METHODS
Reagents. Human recombinant BMP2 protein was obtained from ProSpec (Ness-Ziona, Israel). DMH1 was purchased from the Vanderbilt University Chemical Synthesis Core (Nashville, Tenn). For controls, the vehicle dimethyl sulfoxide was used in similar amounts and concentrations as in treated groups. All chemicals were purchased from Sigma-Aldrich (St. Louis, Mo).
Vascular SMC culture. Human aortic SMCs (HASMCs) were obtained from ATCC (Manassas, Va). HASMCs were cultured in Dulbecco modified Eagle medium containing 10% fetal bovine serum at 37 C in a humidified, 5% CO 2 incubator. To induce calcification, confluent HASMCs were cultured in a calcification medium containing 3.0 mM inorganic phosphate (Pi) for 7 days.
Aortic ring organ culture. Animal experiments were performed in accordance with guidelines of the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. Thoracic aortas were harvested from Sprague Dawley rats (250 g), gently cleared of surrounding tissues, and cut into 0.5-cm-long segments. Arterial calcification was induced as previously described. 20 Briefly, aortic segments were incubated in calcification culture medium (Dulbecco modified Eagle medium with 100 units/mL penicillin and 100 mg/mL streptomycin) containing 3.8 mM Pi in the absence or presence of BMP inhibitor DMH1 for 7 days at 37 C in a humidified 5% CO 2 incubator.
Calcium assay. For HASMC culture, at the end of the experiment, cells were washed with phosphate-buffered saline and directly decalcified in 300 mL of 0.6 N HCl for 24 hours. For aortic ring organ culture, after 7 days, the segments were dried and weighed and then decalcified in 200 mL of 0.6 N HCl for 24 hours. Calcium content was measured using the o-cresolphthalein complexone method. 21 Western blot. Western blot was performed as previously described. 22 Briefly, lysates were prepared in RIPA buffer with protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany). The concentrations of total proteins were measured by BCA protein assay (Thermo Fisher Scientific, Waltham, Mass). Total lysates were loaded on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electrotransferred into nitrocellulose membrane. The primary antibodies against smooth muscle myosin heavy chain (SM-MHC; Biomedical Technology, Stoughton, Mass; BT-562), SM22a (Abcam, Cambridge, Mass; ab14106), osterix (Abcam, ab94744), alkaline phosphatase (Santa Cruz Biotechnology, Santa Cruz, Calif; sc-137213), p-Smad 1/5/8 (Cell Signaling Technology, Danvers, Mass; 9511s), Smad (Santa Cruz; sc-7153), and horseradish peroxidase-coupled secondary antibodies were used. The signals were visualized using enhanced chemiluminescence reagents (Thermo Fisher Scientific). The density of protein expression was quantified by using ImageJ (National Institutes of Health, Bethesda, Md).
Histology and immunohistochemistry. After organ culture for 7 days, thoracic aorta segments were washed with phosphate-buffered saline and fixed with 10% neutral buffer formalin. The specimens were then embedded in paraffin, and 5-mm cross sections were cut. The sections were deparaffinized, and hematoxylin and eosin staining was performed. Arterial medial calcification was visualized using alizarin red S staining as previously described. 23 For immunohistochemistry, the sections were deparaffinized, followed by treatment with citrate buffer for antigen retrieval and 3% H 2 O 2 . The sections were blocked with Dako serum-free blocking solution (Dako North America, Carpinteria, Calif) and incubated with primary antibody overnight at 4 C. The primary antibodies included SM22a (Abcam, ab14106) and osterix (Abcam, ab94744). Subsequently, the sections were incubated with biotinylated secondary antibodies for 30 minutes at room temperature. Avidin-biotinylated enzyme complex (Vector Laboratories, Burlingame, Calif) and a diaminobenzidine substrate chromogen system (Dako North America) were used for detection. Sections were counterstained with hematoxylin. The images were captured by Olympus DP260.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad, La Jolla, Calif). Differences were analyzed by Student t-test. P values < .05 were considered significant.
RESULTS
DMH1 suppresses phosphate-induced calcification in vascular SMCs. To study the effects of BMP receptor inhibition on vascular SMC calcification in vitro, confluent HASMCs were induced to calcify by culturing in medium containing 3.0 mM Pi for 7 days. As shown in Fig 1, A, treatment with 3.0 mM Pi resulted in extensive alizarin red S staining compared with normal phosphate levels, indicating that Pi induces calcification. However, in the presence of DMH1, the effect of calcification was suppressed, and 5 mM DMH1 markedly reduced Pi-induced calcium deposition. Quantification of calcium accumulation by use of the o-cresolphthalein complexone method showed that DMH1 dose dependently attenuated Pi-induced calcium accumulation in HASMCs, and 5 mM DMH1 caused a 50% reduction of calcium accumulation (Fig 1, B) .
To investigate whether DMH1 could reduce calcification in the setting of increased BMP2 protein levels, recombinant BMP2 was added to calcification culture medium. As shown in Fig 1, C, the addition of BMP2 further elevated Pi-induced calcium accumulation, but DMH1 blocked it. These data suggest that blocking of BMP signaling can suppress Pi-induced SMC calcification.
We next assessed the effects of Pi on the expression of BMPs and their receptors using qPCR. In HASMCs, the messenger RNA (mRNA) levels of BMP2 and BMP4 were significantly increased after treatment with 3 mM Pi compared with control, whereas levels of the BMP receptors 1A (ALK3) and activin A receptor type 1 (ALK2) were not altered (Fig 2, A) . We also found that DMH1 could decrease the mRNA expression of BMP2 and BMP4 but not of ALK2 or ALK3 (Fig 2, A) . To investigate whether DMH1 is able to suppress BMP receptor activation, its downstream signaling molecule Smad1/5/8 was assessed by Western blot. HASMCs were treated with either recombinant BMP2 or Pi in the presence or absence of DMH1 for 24 hours. DMH1 markedly decreased p-Smad1/5/8 levels in BMP2-treated HASMCs (Fig 2,  B, left panel) . DMH1 also decreased p-Smad1/5/8 expression in Pi-treated HASMCs (Fig 2, B, right panel) .
DMH1 reduces phosphate-induced osteogenic differentiation. Vascular SMCs are able to undergo osteogenic transformation, a change in phenotype to a more bonelike cell, when they are exposed to elevated phosphate levels. 24 Such cellular changes are thought to play a critical role in calcification. To determine whether DMH1 affects osteogenic differentiation in vascular SMCs, confluent HASMCs were cultured in high Pi (3 mM) calcification medium for 7 days, and osteoblast markers were examined by Western blot. As shown in Fig 3, the osteoblast markers osterix and alkaline phosphatase were significantly induced in Pi-treated SMCs compared with control. However, this effect was reduced by treatment with DMH1. In contrast, SM-MHC and SM22a were decreased by Pi and partially restored by DMH1. These data suggest that blocking of BMP receptor activation can inhibit calcification by influencing osteogenic transformation of SMCs. DMH1 attenuates medial artery calcification. To study the effects of DMH1 in whole artery segments, we used an organ culture system that results in mineral deposition within the media. In this model, calcium hydroxyapatite is deposited on medial elastin in a manner analogous to the calcification seen in patients with diabetes and chronic renal failure. This method has been validated recently as a model of medial calcification that is sensitive to age and diabetes similar to that in humans. 25 Harvested thoracic aortas from Sprague Dawley rats were cultured in calcification medium containing 3.8 mM Pi with or without indicated concentrations of DMH1 for 7 days. Alizarin red S staining was used to visualize the extent of calcium deposition. As shown in Fig 4, A, in untreated control aortas, calcification is almost undetectable. After treatment with 3.8 mM phosphate for 7 days, aortas showed extensive calcification within the smooth muscle medial layer as revealed by alizarin red S staining. However, this effect was largely diminished by the treatment with DMH1. Accordingly, the osteogenic marker osterix was increased by Pi, whereas it was suppressed by DMH1. Consistent with the histologic findings, treatment with DMH1 also significantly reduced calcium concentration in the Pi-treated aortas as determined by calcium assay (Fig 4, B) .
DISCUSSION
In this study, we demonstrate that DMH1, a highly selective BMP inhibitor, reduces SMC calcification and osteogenic transformation. We further show that it inhibits activation of downstream signaling molecules in vitro and elastin mineralization in an organ culture model of medial artery calcification. Our data suggest that inhibition of BMP signaling using synthetic, small-molecule inhibitors may be a useful strategy to reduce medial artery calcification in patients.
Arterial calcification has emerged as a critical and independent predictor of morbidity and mortality in patients with cardiovascular disease. 9, 26 It is particularly important in patients with diabetes and chronic kidney disease. 1, 7 A driving mechanism in patients with end-stage kidney disease is the associated disturbances of phosphate metabolism. 1, 27 To date, no effective therapeutic strategies have become available. Vascular SMCs exposed to elevated phosphate levels develop bone cell-like characteristics, including the ability to secrete matrix vesicles. 28 They also demonstrate increased expression of osteogenic markers, including the transcription factors BMP2, Cbfa1/Runx2, Msx2, alkaline phosphatase, and osteopontin, whereas markers of the SMC phenotype including SM-MHC and SM22a are decreased. 28 Considerable data support the concept that BMP signaling is involved in the vascular calcification that develops in chronic kidney disease. 29, 30 Pi increases BMP2 expression at both the mRNA and protein levels. 31 SMC treatment with BMP2 further enhances Pi-induced osteochondrogenic modulation and SMC calcification, and Pit-1 plays a crucial role in BMP2-regulated SMC calcification. 16 In this series of studies, we show that BMP2 and BMP4 are increased by the addition of Pi to culture medium. DMH1 treatment suppressed Pi-induced upregulation of BMP2 and BMP4 mRNA. The mechanisms behind this effect warrant further investigation. We further demonstrate that addition of the small-molecule BMP inhibitor can suppress SMC dedifferentiation while reducing activation of the BMP receptor pathway. Our data appear to suggest that there are effects of Pi on SMC dedifferentiation that are independent of BMP signaling because DMH1 failed to completely restore SMC markers. We believe this is because Pi triggers osteogenic transformation of SMCs through multiple mechanisms, although it is also possible that Pi-induced osteogenic transformation occurs earlier than the decrease in SMC markers expression. Although the mechanisms of BMP-induced calcification are not fully understood, our present findings suggest that DMH1 attenuates SMC and aortic medial calcification through inhibition of BMP receptor/Smad1/5/8 signaling.
Several strategies for manipulating BMP signaling have been established. These include the use of endogenous antagonists such as noggin and chordin, soluble coreceptors, and neutralizing antibodies. [32] [33] [34] [35] Dorsomorphin was identified as the first inhibitor of BMP signaling and has been demonstrated to selectively inhibit the BMP type 1 receptors ALK2, ALK3, and ALK6. It can block BMP-induced Smad1/5/8 phosphorylation and attenuate BMP4-and BMP6-induced osteoblastic differentiation. 36 LDN-193189, a dorsomorphin analogue, potently suppresses BMP4-induced Smad1/5/8 activation and inhibits transcriptional activity of the BMP type 1 receptors ALK2 and ALK3. It is also able to inhibit vascular calcification and atherosclerosis through its negative effects on BMP2 signaling in LDLR À/À mice fed with a high-fat diet. 18 LDN-193189 prevents endothelial dysfunction and SMC osteogenic differentiation in chronic kidney disease mice. 29 Using LDN-193189, Malhotra et al demonstrated that BMP signaling plays critical roles in the development of vascular calcification in matrix Gla protein-deficient mice. 37 However, recent studies have revealed that dorsomorphin has significant off-target effects, including inhibition of the VEGF type 2 receptor (Flk1/KDR) and angiogenesis. 19 For these reasons, use of a more selective BMP inhibitor may provide benefit and offer greater clinical applicability.
A highly selective second generation of BMP inhibitors based on structure-activity relationship study of dorsomorphin analogues on live zebrafish embryos has been developed recently. These newer molecules specifically target BMP signaling but not VEGF and angiogenesis.
19
DMH1 has been shown to promote cardiac differentiation in mouse embryonic stem cells 38 and to facilitate neurogenesis of human-induced pluripotent stem cells 39 and to inhibit ovarian cancer cell growth. 40 In this study, we found that DMH1 significantly inhibited Pi-and BMP2-induced calcium deposition in HASMCs as revealed by alizarin red S staining and calcium assay. It also blocked Pi-induced osteogenic transformation of SMCs from a contractile to an osteoblast phenotype. Moreover, we showed that DMH1 treatment was able to reduce Pi-induced p-SMAD1/5/8, a key downstream signaling complex involved in BMP signaling, and medial calcification in arterial ring segments. Accumulating data suggest that the aorta organ culture model has become an ideal platform to understand basic mechanisms of medial artery calcification because it maintains arterial architecture. 20, 25, 27 In this study, we show that DMH1 is also capable of reducing elastin calcification in arterial specimens. When we performed immunohistochemical staining for osterix in our aortic specimens, we saw diffusely increased expression that did not correspond to areas of calcification. This is likely because SMC transformation precedes calcium deposition in this model. We did not see intimal hyperplasia in our aortic ring specimens, probably because no serum is added to the medium used in this model. Future investigations involving alternative blocking strategies, such as small interfering RNA or work with BMP or receptor-specific knockout cells, may allow more precise identification of the relevant calcification-related pathways. Additional in vivo studies using specific BMP receptor-deficient mice may provide added impetus for future clinical investigations.
CONCLUSIONS
We demonstrate that the BMP inhibitor DMH1 attenuates SMC calcification and osteogenic differentiation, and it prevents mineralization in an aortic organ culture model. These findings add to the growing evidence suggesting a prominent role for BMPs in arterial calcification and present the possibility of improving outcomes by reducing calcification in our population of vascular patients. 
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